Goldman Sachs equity analysts diverged sharply from Wall Street consensus this week by maintaining their buy rating on Intuitive Surgical, the Sunnyvale-based manufacturer of the da Vinci surgical robot platform, even as shares have fallen 28% since January. The call stands in direct contrast to recent downgrades from Deutsche Bank and Bank of America, both of which slashed price targets on the stock in the past six weeks. Intuitive closed trading Tuesday at its lowest price-to-earnings multiple since late 2023, despite the company reporting continued procedure volume growth and system placements through the first quarter of 2026.
The disconnect between Intuitive's operational performance and its stock price reflects broader uncertainty around healthcare capital spending heading into the second half of 2026. Hospital systems across North America and Europe delayed equipment purchases through the first quarter, citing elevated interest rates and constrained operating margins. Intuitive reported 1,690 da Vinci system placements in Q1 2026, up 11% year-over-year, but investors focused instead on commentary during the April earnings call about longer sales cycles and increased price sensitivity among smaller hospital networks. Deutsche Bank cited those headwinds when it reduced its price target from $485 to $420 in early May. Bank of America followed two weeks later, cutting its target from $510 to $435 and downgrading the stock to neutral. Both firms pointed to margin pressure from competitive pricing and slower-than-expected adoption of the da Vinci 5 system, which Intuitive began shipping in volume in late 2025.
Goldman Sachs analyst Robyn Karnauskas argued in a note to clients that the market has overreacted to near-term cyclical challenges while ignoring the structural growth story in robotics-assisted surgery. Karnauskas maintained a $520 price target and highlighted three data points: da Vinci procedures grew 18% year-over-year in Q1 2026 across all geographies; recurring revenue from instruments and accessories now represents 72% of total revenue, up from 68% three years ago; and Intuitive's installed base reached 9,200 systems worldwide as of March 31, creating a durable annuity stream that should insulate earnings through any prolonged capital spending downturn. The Goldman note specifically called out international growth, where procedure volumes in Asia-Pacific markets rose 26% in the first quarter, driven by new placements in Japan, South Korea, and mainland China. Intuitive has regulatory approval for 22 surgical procedures using da Vinci systems, ranging from prostatectomy and hysterectomy to colorectal resection and mitral valve repair, giving it exposure to multiple high-volume surgical categories.
The debate over Intuitive's valuation arrives as competition intensifies in the robotics-assisted surgery market. Johnson & Johnson began shipping its Ottava surgical robot to select U.S. hospitals in March 2026 following FDA clearance in December. Medtronic's Hugo system, approved in 2024, has gained traction in urology departments at several major academic medical centers. CMR Surgical, the Cambridge-based developer of the Versius system, raised $600 million in Series D funding in February and announced plans to enter the U.S. market pending FDA approval expected in Q4 2026. Analysts at Bank of America cited the shifting competitive landscape as a primary reason for their downgrade, noting that Intuitive's 80% market share in robotics-assisted surgery could face erosion as hospitals seek lower-cost alternatives. The da Vinci 5 system carries a list price of approximately $2.5 million, while Ottava and Hugo both entered the market at price points 15-20% below comparable da Vinci configurations. Instrument costs per procedure average $1,800-$2,200 for da Vinci systems, representing another area where competitors aim to undercut Intuitive's economics.
Intuitive has responded by accelerating its software and ecosystem strategy. The company launched My Intuitive in January, a cloud-based platform that aggregates surgical data, instrument usage, and performance analytics across hospital systems. Twelve large U.S. health networks have signed multi-year agreements for My Intuitive, which Intuitive positions as a value-added service that deepens customer relationships and creates switching costs. The company also expanded its training infrastructure, opening three new simulation centers in Houston, London, and Singapore during the first quarter. CEO Gary Guthart said on the May earnings call that Intuitive trained more than 4,200 surgeons on da Vinci systems in Q1 2026 alone, up from 3,100 in the year-ago period. That investment in surgeon education represents a long-term moat, as surgeons trained on one platform rarely switch to competing systems during their careers. Goldman Sachs pointed to this dynamic in its contrarian call, arguing that Intuitive's first-mover advantage and installed base make it difficult for competitors to displace the company even with lower prices. Procedure volumes drive instrument revenue, and with more than 75,000 surgeons worldwide now credentialed on da Vinci systems, Intuitive's annuity revenue stream appears resilient regardless of near-term capital equipment headwinds.
What to Watch: Intuitive reports Q2 2026 earnings in mid-July; watch for commentary on da Vinci 5 adoption rates and any change in guidance for full-year system placements. CMR Surgical's FDA decision is expected in October or November, which could trigger another round of valuation pressure if approval comes through. Johnson & Johnson plans to release six-month clinical data on Ottava procedures at the American College of Surgeons meeting in San Francisco this October, giving the market its first real-world look at how the platform performs against da Vinci in head-to-head hospital deployments. Goldman Sachs has a price target review scheduled for September following the company's investor day.
